Gene therapy for osteoarthritis

Gene transfer strategies for medical management of the Osteoarthritis have attracted the attention of scientists due to the complex pathology of this chronic disease. Unlike other pharmacological treatments, gene therapy targets the disease process rather than the symptoms.[1]

Theory

Passing from parents to children, genes are the building blocks of inheritance. They contain instructions for making proteins. If genes do not produce the right proteins in a correct way, a child can have a genetic disorder. Gene therapy is a molecular method aiming to replace defective or absent genes, or to counteract the ones undergoing overexpression. For this purpose, three techniques may be utilized: gene isolation, manipulations, and transferring to target cells.[2] The most common form of gene therapy involves inserting a normal gene to replace an abnormal gene. Other approaches including repairing an abnormal gene and altering the degree to which a gene is turned on or off. Two basic methodologies are utilized to transfer vectors into target tissues; Ex vivo gene transfer and In-vivo gene transfer. One type of gene therapy in which the gene transfer takes place outside the patient's body is called ex vivo gene therapy. This method of gene therapy is more complicated but safer since it is possibile to culture, test, and control the modified cells.

Significance and causes of osteoarthritis

Osteoarthritis (OA) is a degenerative joint disease which is the western world's leading cause of pain and disability.[3][4] It is characterized by the progressive loss of normal structure and function of articular cartilage, the smooth tissue covering the end of the moving bones.[5] This chronic disease not only affects the articular cartilage but the subchondral bone, the synovium and periarticular tissues are other candidates.[3] People with OA can experience severe pain and limited motion. OA is mostly the result of natural aging of the joint due to biochemical changes in the cartilage extracellular matrix.[4][6]

Osteoarthritis is caused by mechanical factors such as obesity, joint trauma, mechanical overloading of joints or joint-instability.[6] Genetics is also a leading factor that contributes to OA. Studies have shown that genetics is the source of at least 50% of OA cases in the hands and hips. Since the degeneration of cartilage is an irreversible phenomenon, it is incurable, costly and responds poorly to treatment.[3] Due to the prevalence of this disease nowadays, the repair and regeneration of articular cartilage has become a dominant area of research.[5] The growing number of the patients suffering from osteoarthritis and the effectiveness of the current treatments attract a great deal of attention to genetic-based therapeutic methods to cure and prevent the progression of this chronic disease.

Vectors for osteoarthritis gene delivery

Various vectors have been developed to carry the therapeutic genes to cells. There are two broad categories of gene delivery vectors: Viral vectors, involving viruses and non-viral agents, such as polymers and liposomes.[7]

Viral vectors

Viral vectors proved to be more successful in transfecting cells as their life cycles require them to transfer their own genes to the host cells with high efficiency. A virus infects the human by inserting its gene directly into his cells. This can be deadly, but the brilliant idea is to take advantage of this natural ability. The idea is to remove all the dangerous genes in the virus and inject the healthy human genes. So, viruses are inserting positive elements to the host cells while attacking them and they will be helpful rather than harmful.[8]

While viral vectors are 40% more efficient in transferring genes, they are not fully appreciated for in vivo gene delivery because of their further adverse effects. Primarily, viral vectors induce an inflammatory response, which can cause minor side effects such as mild edema or serious ones like multisystem organ failure. It is also difficult to administer gene therapy repeatedly due to the immune system's enhanced response to viruses. Furthermore, viruses may spread out to other organs after intraarticular injection and this will be an important disadvantage.[9] However, majority of problems associated with gene delivery using viral vectors solved by ex vivo gene delivery method. In Osteoarthritis gene therapy, ex vivo method makes it possible to transfect not only the cells of the synovial lining of joints but also articular chondrocytes and chondroprogenitor cells in cartilage.[10]

Non-viral vectors

Non-viral methods involve complexing therapeutic DNA to various macromolecules including cationic lipids and liposomes, polymers, polyamines and polyethylenimine, and nanoparticles. FuGene 6 [11] and modified cationic liposomes [12] are two non-viral gene delivery methods that have so far been utilized for gene delivery to cartilage. FuGene 6 is a non-liposomal lipid formulation, which has proved to be successful in transfecting a variety of cell lines. Liposomes have shown to be an appropriate candidate for gene delivery,[13] where cationic liposomes are made to facilitate the interaction with the cell membranes and nucleic acids.[14] Unlike viral vectors, non-viral ones avoid the risk of acquiring replication competence. They have the capacity to deliver a large amount of therapeutic genes repeatedly, and it is convenient to produce them on a large scale. The most important of all, they do not elicit immune responses in the host organism. In spite of having advantages, non-viral vectors have not yet replaced viral vectors due to relatively low efficiency and short-term transgene expression.[7]

Novel non-viral vectors for osteoarthritis gene delivery including polymeric vectors are still under investigations.

Target cells in osteoarthritis gene therapy

Target cells in the OA therapy are autologous chondrocytes, Chondroprogenitor cells, Cells within the synovial cavity,[7] and cells of adjacent tissues such as muscle, tendons, ligaments, and meniscus. Development of cartilage function and structure may be achieved by:

Approaches influencing several of these processes simultaneously have also shown to be successful, like transferring the combination of inhibitors of catabolism pathways and activators of anabolic events (IGF-I/IL-1RA),[16] as well as that of activators of anabolic and proliferative processes (FGF- 2/SOX9 or FGF-2/IGF-I).[15]

Gene defects leading to osteoarthritis

Osteoarthritis has a great degree of heritability.[17] Forms of osteoarthritis caused by single gene mutation have better chance of treatment by gene therapy.[3] Epidemiological studies have shown that a genetic component may be an important risk factor in OA.[18] Insulin-like growth factor I genes (IGF-1), Transforming growth factorβ, cartilage oligomeric matrix protein, bone morphogenetic protein, and other anabolic gene candidates are among the candidate genes for OA.[7] Genetic changes in OA can lead to defects of a structural protein such as collagen, or changes in the metabolism of bone and cartilage. OA is rarely considered as a simple disorder following Mendelian inheritance being predominantly a multifactorial disease.

However in the field of OA gene therapy, researches has more focused on gene transfer as a delivery system for therapeutic gene products, rather counteracting genetic abnormalities or polymorphisms. Genes, which contribute to protect and restore the matrix of articular cartilage, are attracting the most attention. These Genes are listed in Table 1. Among all candidates listed below, proteins that block the actions of interleukin-1 (IL-1) or that promote the synthesis of cartilage matrix molecules have received the most experimental scrutiny.[8]

Table 1- Candidates for OA gene therapy [3][8]
Category Gene Candidate
Cytokine/cytokine antagonist IL-1Ra, sIL-1R, sTNFR, IL-4
Cartilage growth factor IGF-1, FGF, BMPs, TGF, CGDF
Matrix breakdown inhibitor TIMPs, PAIs, serpins
Signaling molecule/transcription factor Smad, Sox-9, IkB
Apoptosis Inhibitor Bcl-2
Extra cellular matrix molecule Type II collagen, COMP
Free radical antagonist Super Oxide Dismutase

Interleukin-1 as a target in osteoarthritis

Researches suggest that among all potential mediators, a protein called Interleukin-1 is by far the most potent cause of the pain, joint inflammation and loss of cartilage associated with osteoarthritis.[19] A therapeutic gene used to treat the arthritic joins produces a second protein, which naturally counteracts the effect of interleukin-1.[20] The Interleukin 1 receptor antagonist (IL-1Ra), the natural agonist of IL-1, is a protein that binds non-productively to the cell surface of interleukin-1 receptor, therefore blocks the activities of IL-1 by preventing it from sending a signal to IL-1 receptor.[21][22] There are three main researches that prove the benefits of local IL-1Ra gene therapy in animal models of osteoarthritis [4]. Series of experiments on canines, rabbits, and horses demonstrate that local IL-1Ra gene therapy is safe and effective in animal models of OA, according to the fact that recombinant human IL-1Ra strongly protected the articular cartilage from degenerative changes.[23][24][25]

Strategies for osteoarthritis gene therapy

In the context of OA, the most attractive intra- articular sites for gene transfer are the synovium and the articular cartilage. Most experimental progress has been made with gene transfer to a convenient intra-articular tissue, such as the synovium, a tissue amenable to genetic modification by a variety of vectors, using both in vivo and ex vivo protocols.

Gene transfer to synovium

The major purpose of gene delivery is to alter the lining of the joint in a way that enables them to serve as an endogenous source of therapeutic molecules (Table-1) therapeutic molecules can diffuse and influence the metabolism of adjacent tissues such as cartilage. Genes may be delivered to synovium in animal models of RA and OA by direct, in vivo injection of vector or by indirect, ex vivo methods involving autologous synovial cells, skin fibroblasts, or other cell types such as mesenchymal stem cells. The direct in vivo approach is intra-articular insertion of a vector to affect synovicytes. Vectors play crucial role in success of this method.[26] The effect of Differen vectors for in vivo gene delivery to synovium is summarized in Table 2:

Table 2- Performance of different vectors for in vivo gene delivery to synovium [8]
Vector Comment
Non-viral Vectors Short-term and less efficient transfection; many inflammatory
Retrovirus No transduction of normal synovium; modest transduction of inflamed synovium
Lentivirus Extremely high transduction and transgene expression; no obvious side effects
Adenovirus High transduction efficiency; dose-dependent inflammatory response
Adeno-associated virus Moderate levels of transduction of normal and inflamed synovium
Herpes simplex virus Highly efficient transduction; cytotoxic

The indirect ex vivo approach involves harvest of synovium, isolation and culture of synoviocytes, in vitro transduction, and injection of engineered synovicytes into the joint.[27]

Gene transfer to cartilage

Contrary to the synoviocytes which are dividing cells and can be efficacy transduced in vivo using either liposomes or viral vectors, in vivo delivery of genes to chondrocytes is hindered by the dense extra cellular matrix that surrounds these cells. Chondrocytes are non- dividing cells, embedded in a network of collagens and proteoglycans; however researches suggest that genes can be transferred to chondrocytes within normal cartilage by intraarticular injection of liposomes containing sendai virus (HVJ- liposomes) [28] and adeno-associated virus.[29][30]

Most efficient methods of gene transfer to cartilage have involved ex vivo strategies using chondrocytes or chondroprogenitor cells. Chondrocytes are genetically enhanced by transferring complementary DNA encoding IL-1RA, IGF-1, or matrix break down inhibitors mentioned in Table 1. As discussed before, the transplanted cells could serve as an intra- articular source of therapeutic molecules.[8]

Safety

One important issue related to human gene therapy is safety, particularly for the gene therapy of non-fatal diseases such as OA. The main concern is the high immunogenicity of certain viral vectors. Retroviral vectors integrate into the chromosomes of the cells they infect. There will be always a chance of integrating into a tumor suppressor gene or an oncogene, leading to virulent transformation of the cell.[31] In general, gene transfer to humans is considered as a safe therapeutic method, despite recent events that have provided examples of random adverse events. In the first adverse event, adenovirus was used as vector. In 1999 a patient developed a high fever four hours after delivery of the viruses and died from multi-organ failure within 4 days. The immediate appearance of symptoms shows activation of the innate immune system in response to viruses. It is however, worth mentioning that recombinant adenovirus vectors have been utilized in over 600 additional subjects taking part in over 170 different clinical trials without causing a serious threat to human health.[32] Therefore, adenovirus vectors can be statistically considered as safe for OA gene therapy.

Another serious adverse event occurred in children with fatal X-linked severe combined immunodeficiency caused by a mutation in one chain of a cytokine receptor. They were successfully treated by an ex vivo procedure in which a retrovirus was used to transfer a wild-type copy of the affected gene to the subjects' hematopoietic stem cells. However, two of the children developed leukemia. This seems to be the result of the insertion of the retrovirus near an oncogene. Overall, retroviruses have been the most widely used vectors for gene transfer to humans and no other records of adverse effect exist related to use of this vector.[32] The majority of experiences in transferring gene to humans justifies that this method can be accomplished safely, however a great deal of attention should be paid to preparation protocols.

See also

References

  1. ↑ T. Pap, J. Schedel, G. Pap, U. Moller-Ladner, R.E. Gay, S. Gay C. Guincamp (2000). "Gene therapy in osteoarthritis". Joint Bone Spine.
  2. ↑ C. Wayne McIlwraith David D. Frisbie; McIlwraith, C. W. (Aug 2001). "Gene Therapy: Future Therapies in Osteoarthritis". Vet Clin North Am Equine Pract 17 (2): 233–243. PMID 15658173.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 CH Evans,JN Gouze, E Gouze, PD Robbins and SC Ghivizzani (2004). "Osteoarthritis gene therapy". Gene Therapy: 379–389.
  4. ↑ 4.0 4.1 Madry, H., Luyten, F.P., and Facchini, A (2011). "Biological aspects of early osteoarthritis". Knee Surgery, Sports Traumatology, Arthroscopy.
  5. ↑ 5.0 5.1 Buckwalter, J.A., and Mankin, H.J., Esa; Nevalainen, Pasi; Eskelinen, Antti; Huotari, Kaisa; Kalliovalkama, Jarkko; Moilanen, Teemu (1997). "Instructional Course Lectures, The American Academy of Ortopaedic Surgeons – Articular cartilage: Part II.Degeneration and osteoarthritis, repair, regeneration, and transplantation". J Bone Joint Surg Am. 4 79 (14): 612–632. doi:10.2106/JBJS.J.01935.
  6. ↑ 6.0 6.1 . Felson, D.T., Lawrence, R.C., Dieppe, P.A., Hirsch, R., David T. et al. (2000). "Osteoarthritis: new insights. Part 1: the disease and its risk factors". Annals of Internal Medicine 133 (8): 635–646. doi:10.7326/0003-4819-133-8-200010170-00016. PMID 11033593.
  7. ↑ 7.0 7.1 7.2 7.3 Antonios G. Mikos A. Saraf (2006). "Gene delivery strategies for cartilage tissue engineering". Advanced Drug Delivery Reviews: 592–603.
  8. ↑ 8.0 8.1 8.2 8.3 8.4 Christopher H. Evans, Christopher H. (2004). "Gene Therapies for Osteoarthritis". Current Rheumatology Reports 6 (1): 31–40. doi:10.1007/s11926-004-0081-5. PMID 14713400.
  9. ↑ N. Somia I.M. Verma, Inder M.; Somia, Nikunj (1997). "Gene Therapy — promises, problems and prospects". Nature 389 (6648): 239–242. Bibcode:1997Natur.389..239V. doi:10.1038/38410. PMID 9305836.
  10. ↑ Q.J. Jiang K. Gelse et al. (2001). "Fibroblast-mediated delivery of growth factor complementary DNA into mouse joints induces chondrogenesis but avoids the disadvantages of direct viral gene transfer". Arthritis Rheum: 1943–1953.
  11. ↑ G. Kaul H. Madry et al. (2005). "Trippel, Enhanced repair of articular cartilage defects in vivo by transplanted chondrocytes overexpressing insulin-like growth factor I (IGF-I)". Gene Therapy: 1171–1179.
  12. ↑ T.M. Maris, R. Gelberman, M. Boyer, M. Silva, D. Amiel R.S. Goomer (2000). "Nonviral in vivo Gene Therapy for tissue engineering of articular cartilage and tendon repair". Clin. Orthop.Relat.Res: 189–200.
  13. ↑ Verwaerde, C. Jacquet, C. Auriault, J. Sany, C. Jorgensen F. Apparailly (1998). "Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis". Journal of Immunology: 5213–5220.
  14. ↑ J. Honiger, D. Damotte, A. Minty, C. Fournier, D. Fradelizi, M. Boissier N. Bessis (1999). "Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-4 or IL-13 ameliorates murine collagen-induced arthritis (CIA)". Clinical & Experimental Immunology: 376–382.
  15. ↑ 15.0 15.1 Magali Cucchiarini and Henning Madry. "Magali Cucchiarini and Henning Madry". Experimental Orthopaedics and Osteoarthritis Research, Saarland University Medical Center. Homburg/Saar.
  16. ↑ Haupt JL et al. (2005). "Transduction of insulin-like growth factor-I and interleukin-1 receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model". Journal of Orthopaedic Research: 118–126.
  17. ↑ MacGregor AJ (2000). "The genetic contribution to radiographic hip osteoarthritis in women: results of a classic twin study". Arthritis Rheum: 2410–2416.
  18. ↑ Piercarlo Sarzi-Puttini et al. (2005). "Osteoarthritis: An Overview of the Disease and Its Treatment Strategies". Seminars in Arthritis and Rheumatism 35 (1): 1–10. doi:10.1016/j.semarthrit.2005.01.013. PMID 16084227.
  19. ↑ Cole AA Kuettner KE, K; Cole, A (Feb 2005). "Cartilage degeneration in different human joints". Osteoarthritis Cartilage 13 (2): 93–103. doi:10.1016/j.joca.2004.11.006. PMID 15694570.
  20. ↑ Dinarello CA (2003). Interleukin-1 family;The Cytokine Handbook. London: Academic Press.
  21. ↑ Spurr NK, Cox S, Jeggo P, Sim RB Steinkasserer A; Spurr, N. K.; Cox, S; Jeggo, P; Sim, R. B. (July 1992). "The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci". Genomics 13 (3): 654–657. doi:10.1016/0888-7543(92)90137-H. PMID 1386337.
  22. ↑ Evans CH Arend WP (2003). "Interleukin-1 receptor antagonist". The Cytokine Handbook,Lotze MT Edited by Thomson AW, London: 669–708.
  23. ↑ Fernandes JC, Martel-Pelletier J Caron JP et al. (1996). "Chondroprotective effect of intra-articular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression". Arthritis Rheum: 1535–1544.
  24. ↑ Tardif G, Martel-Pelletier J Fernandes J et al. (1999). "In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression". American Journal of Pathology: 1159–1169.
  25. ↑ Ghivizzani SC, Robbins PD Frisbie DD et al. (2002). "Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene". Gene Therapy: 12–20.
  26. ↑ C. H. and Robbins, P. D. Evans (1994). "Gene therapy for arthritis". Gene Therapeutics, J. A. Wolff, Edition: 320–343.
  27. ↑ G Bandara, G. et al. (1990). "Intraarticular expression of biologically active interleukin-1 receptor antagonist protein by ex vivo gene transfer". Proc. Natl. Acad. Sci. U.S.A. 90 (22): 10764–10768. Bibcode:1993PNAS...9010764B. doi:10.1073/pnas.90.22.10764. PMID 8248169.
  28. ↑ Hashimoto H, Tomita N Tomita T et al. (1997). "In vivo direct gene transfer into articular cartilage by intra-articular injection mediated by HVJ (sendai) virus and liposomes". Arthritis Rheum: 901–906.
  29. ↑ Schwartz E (2000). "The adeno-associated virus vector for orthopaedic gene therapy". Clinical Orthopaedics and Related Research: 31–40.
  30. ↑ Yoo U, Mandell I, Angele P et al. (2000). "Chondroprogenitor cells and gene therapy". Clin Orthop: 164–170.
  31. ↑ Anderson WF, W. (1992). "Human gene therapy". Science 256 (5058): 808–813. doi:10.1126/science.1589762. PMID 1589762.
  32. ↑ 32.0 32.1 apy/clinical "Web site of the Journal of Gene Medicine". Retrieved Aug 2003.